Autumn Research Update Meeting 2025
Our 2025 Autumn Research Update Meeting will take place once again at the renowned Royal Society of Medicine (RSM), Wimpole Street, London, on Monday 10 November, where guests can look forward to an engaging agenda featuring the latest updates from our funded research. Theme: Revolutionising...
Learn more
Webinar – Exercise and Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. Re-watch our webinar discussing recent publications around the theme of exercise in Parkinson’s. The panel, once again chaired by Van Andel Institute’s Professor Patrik Brundin comprises clinical expertise from Professor Bas Bloem…
IPDGC 2019: London
The International Parkinson Disease Genomics Consortium (IPDGC) held their annual meeting in London in December. Over 150 researchers working on the genetics of Parkinson’s attended the two-day event which was sponsored by Cure Parkinson’s. The IPDGC is a group of highly collaborative scientists, who are…
Clinical trial for Anle138b
The German biotech company, MODAG, announced that their first drug candidate for neurodegenerative conditions has started phase I safety testing in humans. The drug, Anle138b, is being developed for Parkinson’s and it has previously shown to rescue neurons in pre-clinical models of alpha synuclein-associated Parkinson’s….
Keeping Pace with LRRK2 and GCase
There are a number of genetic variations that can increase one’s risk of developing Parkinson’s. Two of the most common genetic variations or mutations occur in regions of human DNA known as the ‘LRRK2’ gene and the ‘GBA’ gene (a gene being a functional section…
GP2: global Parkinson’s genetics program
In almost every cell of a human body, genetic material or DNA is translated into proteins, referred to as genes. These genes provide the instructions for making and maintaining each individual. Small errors or mutations in certain genes, however, can result in increased risk of…